Potential Involvement of Organic Anion Transporters in Drug Interactions with Shuganning Injection, a Traditional Chinese Patent Medicine

Abstract

Traditional Chinese medicine injections have been widely used in China for the treatment of various diseases. Transporter-mediated drug-drug interactions are a major contributor to adverse drug reactions. However, the research on transporter-mediated Traditional Chinese medicine injection-drug interactions is limited. Shuganning injection is a widely used Traditional Chinese medicine injection for treating various liver diseases. In this study, we investigated the inhibitory effect of Shuganning injection and its four main ingredients (baicalin, geniposide, chlorogenic acid, and oroxylin A) on 9 drug transporters. Shuganning injection strongly inhibited organic anion transporter 1 and organic anion transporter 3 with IC₅₀ values < 0.1% (v/v), and moderately inhibited organic anion transporter 2, organic anion transporting-polypeptide 1B1, and organic anion transporting-polypeptide 1B3 with IC₅₀ values < 1.0%. Baicalin, the most abundant bioactive ingredient in the Shuganning injection, was identified as both an inhibitor and substrate of organic anion transporter 1, organic anion transporter 3, and organic anion transporting-polypeptide 1B3. Oroxylin A had the potential to act as both an inhibitor and substrate of organic anion transporting-polypeptide 1B1 and organic anion transporting-polypeptide 1B3. In contrast, geniposide and chlorogenic acid had no significant inhibitory effect on drug transporters. Notably, Shuganning injection markedly altered the pharmacokinetics of furosemide and atorvastatin in rats. Using Shuganning injection as an example, our findings support the implementation of transporter-mediated Traditional Chinese medicine injection-drug interactions in the development of Traditional Chinese medicine injection standards.

Key words

Transporter - Shuganning injection - drug-drug interaction - Artemisia capillaris - Gardenia jasminoides - Isatis tinctoria - Ganoderma lucidum

Publication History

Received: 02 December 2022

Accepted after revision: 21 April 2023

Article published online:
26 May 2023

• References

• 1 Nigam SK. What do drug transporters really do?. Nat Rev Drug Discov 2015; 14: 29-44
• 2 International Transporter Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. Membrane transporters in drug development. Nat Rev Drug Discov 2010; 9: 215-236
• 3 Sudsakorn S, Bahadduri P, Fretland J, Lu C. 2020 FDA drug-drug interaction guidance: A comparison analysis and action plan by pharmaceutical industrial scientists. Curr Drug Metab 2020; 21: 403-426
• 4 Zheng W, Wu Y, Gao H, Ouyang D. Traditional Chinese medicine injections: where we are after 80-year development. Chin Med 2022; 17: 127
• 5 Li H, Wang S, Yue Z, Ren X, Xia J. Traditional Chinese herbal injection: Current status and future perspectives. Fitoterapia 2018; 129: 249-256
• 6 Wang QY, Duan XT, Li S, Lai HQ, Cheng WN, Ao JW, Zhang JY, Duan CC. Active compounds screening and hepatoprotective mechanism of Shuganning injection based on network pharmacology and experimental validation. Nat Prod Commun 2020; 17: 1-12
• 7 Du J, Wang L, Huang X, Zhang N, Long Z, Yang Y, Zhong F, Zheng B, Lan W, Lin W, Ma W. Shuganning injection, a traditional Chinese patent medicine, induces ferroptosis and suppresses tumor growth in triple-negative breast cancer cells. Phytomedicine 2021; 85: 153551
• 8 Lu H, Lu Z, Li X, Li G, Qiao Y, Borris RP, Zhang Y. Interactions of 172 plant extracts with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8): a study on herb-drug interactions. PeerJ 2017; 5: e3333
• 9 Ma R, Li G, Wang X, Bi Y, Zhang Y. Inhibitory effect of sixteen pharmaceutical excipients on six major organic cation and anion uptake transporters. Xenobiotica 2021; 51: 95-104
• 10 Xiang Y, Liu S, Yang J, Wang Z, Zhang H, Gui C. Investigation of the interactions between flavonoids and human organic anion transporting polypeptide 1B1 using fluorescent substrate and 3D-QSAR analysis. Biochim Biophys Acta Biomembr 2020; 1862: 183210
• 11 Palermo DP, DeGraaf ME, Marotti KR, Rehberg E, Post LE. Production of analytical quantities of recombinant proteins in Chinese hamster ovary cells using sodium butyrate to elevate gene expression. J Biotechnol 1991; 19: 35-47
• 12 Wolman AT, Gionfriddo MR, Heindel GA, Mukhija P, Witkowski S, Bommareddy A, Vanwert AL. Organic anion transporter 3 interacts selectively with lipophilic beta-lactam antibiotics. Drug Metab Dispos 2013; 41: 791-800
• 13 Iwaki M, Shimada H, Irino Y, Take M, Egashira S. Inhibition of methotrexate uptake via organic anion transporters OAT1 and OAT3 by glucuronides of nonsteroidal anti-inflammatory drugs. Biol Pharm Bull 2017; 40: 926-931
• 14 Nagle MA, Wu W, Eraly SA, Nigam SK. Organic anion transport pathways in antiviral handling in choroid plexus in Oat1 (Slc22a6) and Oat3 (Slc22a8) deficient tissue. Neurosci Lett 2013; 534: 133-138
• 15 Burckhardt G. Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 2012; 136: 106-130
• 16 Ma L, Zhao L, Hu H, Qin Y, Bian Y, Jiang H, Zhou H, Yu L, Zeng S. Interaction of five anthraquinones from rhubarb with human organic anion transporter 1 (SLC22A6) and 3 (SLC22A8) and drug-drug interaction in rats. J Ethnopharmacol 2014; 153: 864-871
• 17 Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol 2009; 158: 693-705
• 18 Balasubramanian R, Maideen NMP. HMG-CoA reductase inhibitors (statins) and their drug interactions involving CYP enzymes, P-glycoprotein and OATP transporters-an overview. Curr Drug Metab 2021; 22: 328-341
• 19 Konig J, Seithel A, Gradhand U, Fromm MF. Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch Pharmacol 2006; 372: 432-443
• 20 Shitara Y. Clinical importance of OATP1B1 and OATP1B3 in drug-drug interactions. Drug Metab Pharmacokinet 2011; 26: 220-227
• 21 Yamashiro W, Maeda K, Hirouchi M, Adachi Y, Hu Z, Sugiyama Y. Involvement of transporters in the hepatic uptake and biliary excretion of valsartan, a selective antagonist of the angiotensin II AT1-receptor, in humans. Drug Metab Dispos 2006; 34: 247-1254
• 22 Kang NF, Li M, Hu HJ, Xiao HQ, Liu LQ, Li Y, Li YT, Wang AM, Wang YL, Zhang Y, He F, Gong ZP. [Simultaneous determination of four components of Shuganning Injection in rat plasma by UPLC-MS/MS and its application to a pharmacokinetic study]. Zhongguo Zhong Yao Za Zhi 2020; 45: 2626-2633
• 23 Yang JY, Li M, Zhang CL, Liu D. Pharmacological properties of baicalin on liver diseases: A narrative review. Pharmacol Rep 2021; 73: 1230-1239
• 24 Xu F, Li Z, Zheng J, Gee Cheung FS, Chan T, Zhu L, Zhuge H, Zhou F. The inhibitory effects of the bioactive components isolated from Scutellaria baicalensis on the cellular uptake mediated by the essential solute carrier transporters. J Pharm Sci 2013; 102: 4205-4211
• 25 Bi Y, Wang X, Li H, Tian Y, Han L, Gui C, Zhang Y. 3D-QSAR analysis of the interactions of flavonoids with human organic cation transporter 2. Toxicol Lett 2022; 368: 1-8
• 26 Kalapos-Kovacs B, Magda B, Jani M, Fekete Z, Szabo PT, Antal I, Krajcsi P, Klebovich I. Multiple ABC transporters efflux baicalin. Phytother Res 2015; 29: 1987-1990
• 27 Miao Q, Wang Z, Zhang Y, Miao P, Zhao Y, Zhang Y, Ma S. In vitro potential modulation of baicalin and baicalein on P-glycoprotein activity and expression in Caco-2 cells and rat gut sacs. Pharm Biol 2016; 54: 1548-1556
• 28 Liu J, Li Y, Sun C, Liu S, Yan Y, Pan H, Fan M, Xue L, Nie C, Zhang H, Qian H, Ying H, Wang L. Geniposide reduces cholesterol accumulation and increases its excretion by regulating the FXR-mediated liver-gut crosstalk of bile acids. Pharmacol Res 2020; 152: 104631
• 29 Huang H, Zhang X, Huang Z, Zhang Y, Zhou Z. Geniposide reverses multidrug resistance in vitro and in vivo by inhibiting the efflux function and expression of P-glycoprotein. Exp Ther Med 2017; 13: 437-442
• 30 Wang L, Pan X, Jiang L, Chu Y, Gao S, Jiang X, Zhang Y, Chen Y, Luo S, Peng C. The biological activity mechanism of chlorogenic acid and its applications in food industry: A review. Front Nutr 2022; 9: 943911
• 31 Wang L, Sweet DH. Interaction of natural dietary and herbal anionic compounds and flavonoids with human organic anion transporters 1 (SLC22A6), 3 (SLC22A8), and 4 (SLC22A11). Evid Based Complement Alternat Med 2013; 2013: 612527
• 32 Li H, Lu N, Yu X, Liu X, Hu P, Zhu Y, Shen L, Xu J, Li Z, Guo Q, Hui H. Oroxylin A, a natural compound, mitigates the negative effects of TNFalpha-treated acute myelogenous leukemia cells. Carcinogenesis 2018; 39: 1292-1303
• 33 Ren G, Qin Z, Yang N, Chen H, Fu K, Lu C, Lu Y, Li N, Zhang Y, Chen X, Zhao D. Interactions between Oroxylin A with the solute carrier transporters and ATP-binding cassette transporters: Drug transporters profile for this flavonoid. Chem Biol Interact 2020; 324: 109097
• 34 Bai J, Zhao S, Fan X, Chen Y, Zou X, Hu M, Wang B, Jin J, Wang X, Hu J, Zhang D, Li Y. Inhibitory effects of flavonoids on P-glycoprotein in vitro and in vivo: Food/herb-drug interactions and structure-activity relationships. Toxicol Appl Pharmacol 2019; 369: 49-59
• 35 Go WJ, Ryu JH, Qiang F, Han HK. Evaluation of the flavonoid oroxylin A as an inhibitor of P-glycoprotein-mediated cellular efflux. J Nat Prod 2009; 72: 1616-1619
• 36 Kalapos-Kovacs B, Juhasz V, Temesszentandrasi-Ambrus C, Magda B, Szabo PT, Antal I, Klebovich I, Krajcsi P. Baicalin is a substrate of OATP2B1 and OATP1B3. Phytother Res 2018; 32: 1647-1650
• 37 Chen ZZ, Lu Y, Du SY, Shang KX, Cai CB. Influence of borneol and muscone on geniposide transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model. Int J Pharm 2013; 456: 73-79
• 38 Schwab D, Herling AW, Hemmerle H, Schubert G, Hagenbuch B, Burger HJ. Hepatic uptake of synthetic chlorogenic acid derivatives by the organic anion transport proteins. J Pharmacol Exp Ther 2001; 296: 91-98
• 39 Li N, Hartley DP, Cherrington NJ, Klaassen CD. Tissue expression, ontogeny, and inducibility of rat organic anion transporting polypeptide 4. J Pharmacol Exp Ther 2002; 301: 551-560
• 40 Cattori V, van Montfoort JE, Stieger B, Landmann L, Meijer DK, Winterhalter KH, Meier PJ, Hagenbuch B. Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch 2001; 443: 188-195
• 41 Ishida K, Ullah M, Toth B, Juhasz V, Unadkat JD. Transport kinetics, selective inhibition, and successful prediction of in vivo inhibition of rat hepatic organic anion transporting polypeptides. Drug Metab Dispos 2018; 46: 1251-1258
• 42 Wang G, Bi Y, Xiong H, Bo T, Han L, Zhou L, Zhang C, Zhang Y. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2. Hum Exp Toxicol 2021; 40: S447-S459
• 43 Bajaj R, Chong LB, Zou L, Tsakalozou E, Ni Z, Giacomini KM, Kroetz DL. Interaction of commonly used oral molecular excipients with P-glycoprotein. AAPS J 2021; 23: 106
• 44 Simoff I, Karlgren M, Backlund M, Lindstrom AC, Gaugaz FZ, Matsson P, Artursson P. Complete knockout of endogenous Mdr1 (Abcb1) in MDCK Cells by CRISPR-Cas9. J Pharm Sci 2016; 105: 1017-1021
• 45 Kneuer C, Honscha W, Gabel G, Honscha KU. Adaptive response to increased bile acids: Induction of MDR1 gene expression and P-glycoprotein activity in renal epithelial cells. Pflugers Arch 2007; 454: 587-594
• 46 Lau YY, Okochi H, Huang Y, Benet LZ. Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: Relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism. Drug Metab Dispos 2006; 34: 1175-1181
• 47 Bahrami G, Mohammadi B, Mirzaeei S, Kiani A. Determination of atorvastatin in human serum by reversed-phase high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 826: 41-45
• 48 Abdel-Hamid ME. High-performance liquid chromatography-mass spectrometric analysis of furosemide in plasma and its use in pharmacokinetic studies. Farmaco 2000; 55: 448-454